Gilead Sciences, Inc.

Valuation Analysis

About the Company

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the

Gilead Sciences, Inc. Stock at a Glance

Gilead Sciences, Inc. (GILD) is currently trading at $125.59 with a market capitalization of $155.9B. The trailing P/E ratio stands at 17.09x, with a forward P/E of 12.99x. The 52-week range spans from $104.46 to $157.29; the current price is 20.2% below the yearly high. Year-over-year revenue growth stands at +4.4%. The net profit margin stands at 30.99%.

💰 Dividend

Gilead Sciences, Inc. pays an annual dividend of $3.28 per share, representing a yield of 2.61%. The payout ratio stands at 43.4%.

📊 Analyst Rating

28 analysts rate Gilead Sciences, Inc. (GILD) on consensus: Buy. The average price target is $157.57, implying +25.46% from the current price. Analyst price targets range from $122.00 to $180.00.

Gilead Sciences, Inc.: The Investment Case in Detail

Gilead Sciences, Inc. (GILD) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 54.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 79.37%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 43.36% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

The Bear Case

Revenue growth has slowed to just 4.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

What to Watch Next

• The forward P/E of 12.99x is meaningfully below the trailing 17.09x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 25.46% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Gilead Sciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.